Suraksha Diagnostic Limited has inaugurated one of Eastern India’s largest and most state-of-the-art genomics laboratories. The grand opening event was graced by Professor Sukumar Mukherjee, a distinguished rheumatologist and mentor at Suraksha Diagnostic.

This significant launch comes as West Bengal experiences a resurgence in medical education and services, aligning with Suraksha Diagnostic’s recognition of the urgent need for accessible genomic diagnostics in the region. The new genomics lab is poised to revolutionize preventive care by enabling early, accurate risk detection and more precise treatment planning.

Strategic investment in a growing market
The global genetic testing market is experiencing rapid growth, valued at USD 38.77 billion in 2024 and projected to reach USD 186.64 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 22.5%. In a landmark move to tap into this expanding market, Suraksha Diagnostic has initially invested ₹22 crore in establishing this genomics lab. An additional ₹46 crore investment is planned over the next 24 months, with the ambitious goal of developing one of Asia’s most advanced genomics laboratories. This initiative marks a significant leap forward for West Bengal, Eastern & North-Eastern India, and the broader landscape of precision diagnostics in India.

Comprehensive genetic testing capabilities
The state-of-the-art genomics lab is equipped with a comprehensive suite of advanced technologies, including Cytogenetics, Microarray Technology, Sanger Sequencing, and multiple Next-Generation Sequencers (NGS). These integrated technologies enable the full spectrum of advanced genetic testing, facilitating predictive, preventive, and personalized healthcare solutions.

The lab’s capabilities extend to detecting chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. These insights are crucial for expecting parents, allowing them to make informed decisions with the support of expert genetic counseling.

Pioneering onco-genomics and personalized care
Suraksha Diagnostic’s Genomics Lab is also pioneering in the field of Onco-genomics, offering advanced hereditary cancer testing panels. This enables the early detection of genetic predispositions to various cancers, including breast, ovarian, and colorectal cancers. The lab provides both germline and somatic mutation profiling, essential for personalized cancer risk assessment and tailored treatment plans. With targeted oncology panels powered by NGS, clinicians can now identify actionable mutations, facilitating highly precise therapies. This positions Suraksha Diagnostic as one of the few centers in Eastern India capable of delivering truly personalized oncology diagnostics.

The lab’s detailed genomics testing process begins with Karyotyping for visualizing all 46 chromosomes, followed by Chromosomal Microarray for smaller genetic changes, and FISH technology for specific genetic issues. Sanger Sequencing offers precise individual gene readings, while Next-Generation Sequencing (NGS) scans millions of genetic data points for deeper insights into complex health conditions.

Vision for the future of healthcare
Dr Somnath Chatterjee, Chairman & Joint Managing Director, Suraksha Diagnostic, emphasized the transformative impact of genomics. “A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics – unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalized treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostic is proud to be at the forefront of this revolution.”

Ritu Mittal, Joint Managing Director & CEO, Suraksha Diagnostic, highlighted the lab’s role in making genomic diagnostics integral to healthcare decisions in Eastern India. “We provide end-to-end solutions for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, pediatric, and onco-genetics without the need to send samples out of the region or compromise on quality.”

Suraksha Diagnostic’s long-term vision is to become a national leader in genomics-driven diagnostics, seamlessly integrating advanced technologies into routine clinical care. The company aims to contribute significantly to national health priorities, including rare disease diagnosis, newborn screening, and preventive genomics, while also expanding its research and public health initiatives.